CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3]

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

851 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-02-01

Study Completion Date

2023-06-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this non-interventional study is to emulate the KEYNOTE-189 randomized controlled trial of pembrolizumab for the treatment of metastatic non-small cell lung cancer using real-world, electronic health record data. The main questions this study aims to answer are:

1. Do patients with metastatic non-small cell lung cancer (NSCLC) treated with pemetrexed, cisplatin/carboplatin, and pembrolizumab have improved real-world overall survival (rwOS) and real-world progression-free survival (rwPFS) compared with patients treated with pemetrexed and cisplatin/carboplatin alone?
2. How do the results of this non-interventional study compare to those of the KEYNOTE-189 randomized controlled trial?

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4]

NCT06585189

Metastatic Non Small Cell Lung Cancer

COMPLETED

Emulation of the KEYNOTE-189 Trial Using Electronic Health Records

NCT05908799

Non-small Cell Lung Cancer Metastatic Lung Cancer

COMPLETED

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)

NCT02578680

Non-Small-Cell Lung Carcinoma

COMPLETED PHASE3

Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer

NCT05777603

Advanced Non Small Cell Lung Cancer

RECRUITING PHASE1

Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread

NCT04631029

Extensive Stage Lung Small Cell Carcinoma Malignant Solid Neoplasm Metastatic Malignant Neoplasm in the Brain

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Coalition to Advance Real-World Evidence through Randomized Controlled Trial Emulation (CARE) Initiative is a program designed to build an empirical evidence base for the use of real-world data (RWD) in clinical and regulatory decision-making. Using randomized controlled trials (RCTs) as a benchmark for causal effect estimates, a series of RCT emulations will be conducted across varying trials, real world data sources, and study design elements to better understand under what conditions non-interventional studies, using data generated during routine clinical care, can provide reliable conclusions about drug effectiveness.

In this study, real-world electronic health record (EHR) data will be used to emulate the KEYNOTE-189 efficacy trial of pembrolizumab as first-line therapy in patients with metastatic non-small cell lung cancer (NSCLC) without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) sensitizing mutations. Similarly to the KEYNOTE-189 trial, this study will compare real-world overall survival (rwOS) and real-world progression-free survival (rwPFS) between patients who initiate pemetrexed, platinum-based chemotherapy, and pembrolizumab, and patients who initiate pemetrexed and platinum-based chemotherapy alone.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Nonsmall Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Exposed

Patients initiating pemetrexed, cisplatin or carboplatin, and pembrolizumab as first-line treatment for metastatic NSCLC

Pembrolizumab

Intervention Type DRUG

Pemetrexed

Intervention Type DRUG

Cisplatin

Intervention Type DRUG

Carboplatin

Intervention Type DRUG

Comparator

Patients initiating pemetrexed and cisplatin or carboplatin as first-line treatment for metastatic NSCLC

Pemetrexed

Intervention Type DRUG

Cisplatin

Intervention Type DRUG

Carboplatin

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pembrolizumab

Intervention Type DRUG

Pemetrexed

Intervention Type DRUG

Cisplatin

Intervention Type DRUG

Carboplatin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Non-small cell lung cancer (NSCLC) diagnosis
* Histology not indicative of squamous cell carcinoma
* Metastatic disease
* Epidermal growth factor receptor (EGFR) and Anaplastic lymphoma kinase (ALK)-negative or Kirsten rat sarcoma viral oncogene homolog (KRAS)-positive
* No prior systemic treatment for metastatic NSCLC
* No record of adjuvant or neoadjuvant therapy in the 12 months before metastatic diagnosis
* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or missing or Karnofsky performance status \>=70 or missing
* No lab results indicating inadequate organ function, as defined in the KEYNOTE-189 RCT protocol

Exclusion Criteria

* Histology indicative of squamous cell carcinoma or small cell elements
* Prior systemic treatment for metastatic NSCLC
* Prior antineoplastic biological therapy
* History of major cancer-related surgery in the 3 weeks before study drug initiation
* Radiation therapy to the lung \>30 Gy in the 6 months before study drug initiation
* Prior diagnosis of clinically active diverticulitis, intra-abdominal abscess, or gastrointestinal obstruction
* Diagnosis of a second primary malignant neoplasm
* Diagnosis of brain, central nervous system, and/or spinal cord metastases
* Diagnosis of autoimmune disease and treatment with corticosteroids or immunosuppressive drugs after diagnosis and within the 2 years prior to study drug initiation
* Treatment with a non-topical systemic steroid in each of the 6 months prior to study drug initiation
* Prior treatment with pembrolizumab or any other anti-PD-1, PD-L1, PD-L2 agent or an antibody targeting other immuno-regulatory receptors or mechanisms
* Treatment with non-topical antibiotics, antifungals, or antivirals within 2 weeks after an infection diagnosis in the month prior to study drug initiation
* Diagnosis of human immunodeficiency virus infection
* Diagnosis of acute hepatitis B or C
* Diagnosis of ascites or plural effusion in the 3 months prior to study drug initiation
* Prior diagnosis of interstitial lung disease or diagnosis of pneumonitis and record of treatment with glucocorticoids within 30 days

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No